Abstracts tagged "classification criteria"

Abstract Number: 1733 • ACR Convergence 2021
Classification of Patients with Systemic Lupus Erythematosus Enrolled in 2 Phase 3 Trials by EULAR/ACR 2019 Criteria
Martin Aringer¹, Ian N. Bruce², Richard Furie³, Eric Morand⁴, Emmanuelle Maho⁵, Catharina Lindholm⁶ and Raj Tummala⁷, ¹University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, ²University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁴Monash University, Melbourne, Australia, ⁵BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁶BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁷BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
Background/Purpose: The TULIP-1 and TULIP-2 trials of anifrolumab, an anti–type I IFN receptor mAb, enrolled autoantibody-positive (ANA, anti-dsDNA, and/or anti-Smith [anti-Sm]) patients, who fulfilled the…
Abstract Number: 0335 • ACR Convergence 2021
Performances of Different Classification Criteria for Systemic Lupus Erythematosus in a Single Center Cohort from Turkey
Ege Sinan Torun¹, Erdem Bektaş¹, Fatih Kemik², Murat Bektaş³, Cigdem Cetin⁴, Yasemin Yalcinkaya⁴, Bahar Esen⁴, Ahmet Gül⁵ and Murat Inanc⁶, ¹Istanbul University Istanbul Faculty of Medicine, İstanbul, Turkey, ²Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul, Turkey, ⁴Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁵Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey, ⁶Istanbul University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Recently developed EULAR/ACR classification criteria for systemic lupus erythematosus (SLE) has important differences compared to the 2012 Systemic Lupus International Collaborating Clinics (SLICC) SLE…
Abstract Number: 1834 • ACR Convergence 2021
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a Bio-naïve Patient Population
Marijn Vis¹, Pascal Richette², Ramirez Julio³, Marlies Neuhold⁴, Robert Wapenaar⁵, Elke Theander⁶, Wim Noel⁷, May Shawi⁸, Alexa Kollmeier⁹ and William Tillett¹⁰, ¹Erasmus MC, Badhoevedorp, Netherlands, ²Lariboisiere Hospital, Paris, France, ³Hospital Universitari Clinic, Barcelona, Spain, ⁴Janssen-Cilag, Zug, Switzerland, ⁵Janssen-Cilag BV, Breda, Netherlands, ⁶Janssen Cilag, Lund, Sweden, ⁷Janssen Pharmaceutica, Vilvoorde, Belgium, ⁸Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Guselkumab (GUS), a human monoclonal antibody targeting the interleukin-23p19-subunit, has demonstrated efficacy across joint and skin endpoints at Week 24 (W24) in the Phase…
Abstract Number: 0521 • ACR Convergence 2020
Avoiding Misclassification of Primary Antiphospholipid Syndrome as Systemic Lupus Erythematosus: What Are the Best-performing SLE Classification Criteria?
Flavio Signorelli¹, Gustavo Balbi², Eloisa Bonfa³, Eduardo Borba⁴ and Danieli Andrade⁵, ¹Universidade de São Paulo, Rio de janeiro, Rio de Janeiro, Brazil, ²Universidade de São Paulo, Juiz de Fora, Minas Gerais, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Primary Antiphospholipid Syndrome (PAPS) patients, when submitted to Systemic Lupus Erythematosus (SLE) classification criteria, can be misclassified. The new 2019 ACR/EULAR classification criteria have…
Abstract Number: 0522 • ACR Convergence 2020
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase III Case Collection Results
Medha Barbhaiya¹, Stephane Zuily², Yasaman Ahmadzadeh³, Karen Costenbader⁴, Raymond Naden⁵ and Doruk Erkan⁶, ¹Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, ²Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, ³Hospital for Special Surgery, New York, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, ⁶Hospital for Special Surgery, New York, NY
Background/Purpose: An international multi-disciplinary effort is underway to develop rigorous, new, consensus- and evidence-based classification criteria for Antiphospholipid Syndrome (APS). The methodological approach includes four…
Abstract Number: 0524 • ACR Convergence 2020
Determination of Homogenous Subgroups of Antiphospholipid Syndrome: A Cluster Analysis Based on 509 Cases
Yann Nguyen¹, Cécile Yelnik², Nathalie Morel³, Romain Paule⁴, Pierre-Yves Hatron², Romain Stammler⁵, Léo Plaçais³, Jean-Charles Piette⁶, Luc Mouthon⁷, Eric Hachulla⁸, Marc Lambert², Le Guern Véronique³ and Nathalie Costedoat-Chalumeau⁹, ¹1Department of Internal Medicine, Hôpital Beaujon, APHP Nord, Université de Paris, Clichy, Clichy, France, ²Department of Internal Medicine and Clinical Immunology, National Referral Centre for rare Systemic Auto-immune Diseases North and North-West of France (CeRAINO), CHU Lille, Hôpital Claude Huriez, Lille, France, Lille, France, ³National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, France, ⁴Department of Internal Medicine, Hôpital Foch, Suresnes, France, Suresnes, France, ⁵National Referral Centre for Rare Autoimmune and Systemic Diseases, Department of Internal Medicine, Hôpital Cochin, AP-HP Centre, Université de Paris, Paris, France, Paris, ⁶Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ⁷National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris-Descartes University, Paris, France, ⁸Department of Internal Medicine and Clinical Immunology, Université de Lille, Lille, France, Lille, France, ⁹APHP, Université de Paris, Paris, France
Background/Purpose: Antiphospholipid syndrome (APS) is a heterogeneous disease, with different phenotypes which may widely vary from classical thrombotic or obstetrical manifestations to catastrophic antiphospholipid syndrome…
Abstract Number: 1080 • ACR Convergence 2020
Sensitivity and Specificity of the 2017 EULAR/ACR Criteria for Idiopathic Inflammatory Myopathies in a Cohort of Patients from Latin America
Antonia Maria Valenzuela Vergara¹, Magdalena Torres¹ and Alejandro Deves¹, ¹Pontificia Universidad Catolica de Chile, Santiago de Chile, Chile
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of diseases characterized by muscle inflammation and internal organ involvement. The Bohan & Peter (B&P) criteria…
Abstract Number: 1162 • ACR Convergence 2020
Comparison of Clinicopathologic and Imaging Features Between Chronic Nonbacterial Osteomyelitis and Its Mimickers: A Multi-national 450 Case-Control Study
Yongdong Zhao¹, Raymond Naden², Melissa Oliver³, Zhaoyi Wang⁴, Eveline Wu⁵, Cassyanne Aguiar⁶, Jonathan Akikusa⁷, Ozge Basaran⁸, Kevin Cain¹, Martina Capponi⁹, Nathan Donaldson¹⁰, Emily Fox¹¹, Antonella Insalaco¹², Annette Jansson¹³, Ummusen Kaya Akca¹⁴, Tzielan Lee¹⁵, Edoardo Marrani¹⁶, Kamran Mahmood¹⁷, Elizabeth Murray¹⁸, Farzana Nuruzzaman¹⁹, Karen Onel²⁰, Manuela Pardeo¹², Lauren Potts²¹, Nathan Rogers¹⁰, Anja Schnabel²², Gabriele Simonini²³, Jennifer Soep¹⁰, Sara Stern²⁴, Alexander Theos²⁵, Yujuan Zhang²⁶, Polly Ferguson²⁷, Christian Hedrich²⁸, Fatma Dedeoglu²⁹, Hermann Girschick³⁰, Ronald Laxer³¹ and Seza Ozen³², ¹University of Washington, Seattle, WA, ²Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand, ³Department of Pediatric Rheumatology, Riley Children's Hospital, Carmel, IN, ⁴University of Washington, Bothell, WA, ⁵UNC Chapel Hill, Chapel Hill, NC, ⁶Children's Hospital of the King's Daughters/EVMS, Norfolk, VA, ⁷PRINTO, Istituto Giannina Gaslini, Genova, Italy, ⁸Hospital for Special Surgery, New York City, NY, ⁹IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, ¹⁰Children's Hospital Colorado, Aurora, CO, ¹¹Children's Mercy Kansas City, Kansas City, MO, ¹²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ¹³Dr. von Hauner Children's Hospital, Munich, Germany, ¹⁴Hacettepe University, Division of Pediatric Rheumatology, Department of Pediatrics, Faculty of Medicine, Ankara, Turkey, ¹⁵Stanford University School of Medicine, Palo Alto, CA, ¹⁶University of Florence, Firenze, Italy, ¹⁷Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, England, United Kingdom, ¹⁸CRMO Patient Partner, New York, NY, ¹⁹Stony Brook Children's Hospital, Stony Brook, NY, ²⁰Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ²¹CRMO Patient Partner, Fort Collins, CO, ²²Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ²³Anna Meyer Children's Hospital, Firenze, Italy, ²⁴University of Utah and Primary Children's Hospital, Salt Lake City, UT, ²⁵Georgetown University, DERWOOD, MD, ²⁶Tufts Medical Center, Boston, MA, ²⁷University of Iowa Carver College of Medicine, Iowa City, IA, ²⁸University of Liverpool, Liverpool, United Kingdom, ²⁹Boston Children's Hospital, Boston, MA, ³⁰Vivantes Children’s Hospital, Wuerzburg, Germany, ³¹The Hospital for Sick Children, Toronto, ON, Canada, ³²Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, Ankara, Turkey
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO)/chronic recurrent multifocal osteomyelitis (CRMO) predominantly affects children and young adults. Classification criteria are not available and diagnostic criteria that have…
Abstract Number: 1265 • ACR Convergence 2020
2019 Lupus Classification Criteria Score Predicting Cost of Future Hospitalizations
Saurav Suman¹, Amna Batool², Joshua Keller² and William Neal Roberts², ¹University of Kentucky, Horseheads, NY, ²University of Kentucky, Lexington, KY
Background/Purpose: The latest 2019 Lupus Classification criteria score (CCS) is based on weighted criteria and has been shown to predict 10-year mortality1. Our previous study…
Abstract Number: 1501 • ACR Convergence 2020
Obstetrical Outcome and Thromboses in a Multicentric Cohort of Antiphospholipid Syndrome (APS) Patients with Severe Preeclampsia: An Analysis of APS Classification Criteria
Maddalena Larosa¹, Nathalie Morel², Meriem Belhocine³, Amelia Ruffatti⁴, Nicolas Martin Silva⁵, Romain Paule⁶, Luc Mouthon⁷, Michel Dreyfus⁸, Jean-Charles Piette⁹, Odile Souchaud-Debouverie¹⁰, Catherine Deneux-Tharaux¹¹, Vassilis Tsatsaris¹², Emmanuelle Pannier Metzger¹³, Gaëlle Guettrot-Imbert¹⁴, Veronique Le Guern¹⁵, Andrea Doria¹⁶ and Nathalie Costedoat-Chalumeau¹⁷, ¹Rheumatology Unit-Department of Medicine-University of Padova, Italy, Padova, Veneto, Italy, ²AP-HP, université René-Descartes Paris V, hôpital Cochin, centre de référence maladies auto-immunes et systémiques rares, pôle médecine, service de médecine interne, Paris, France., Paris, Ile-de-France, France, ³Hôpital Sacré-Coeur de Montréal , Montréal, Montreal, QC, Canada, ⁴Department of Medicine, University of Padova, Padova, Veneto, Italy, ⁵Centre Hospitalier et Universitaire de Caen, Caen, France, ⁶Foch Hospital, Paris, France, ⁷Hopital Cochin - Paris University, Paris, France, ⁸CHU de Caen, Caen, France, ⁹Department of Internal Medicine, Hôpital Pitié-Salpêtrière, Paris, France, Paris, France, ¹⁰CENTRE HOSPITALIER UNIVERSITAIRE LA MILETRIE, poitiers, France, ¹¹INSERM U1153, Obstetrical, Perinatal and Pediatric Epidemiology Research Team, Center for Epidemiology and Statistics Sorbonne Paris Cité , Paris Descartes University , Paris , France, Paris, France, ¹²Maternité Port-Royal,Hôpital Cochin, Paris, France, Paris, France, ¹³Maternité Port-Royal,Hôpital Cochin, Paris, France, ¹⁴Médecine Interne,Hôpital Cochin, paris, France, ¹⁵Médecine Interne,Hôpital Cochin, Paris, France, Paris, France, ¹⁶University of Padua, Padua, Italy, ¹⁷APHP, Université de Paris, Paris, France
Background/Purpose: According to APS classification criteria1, clinical manifestations of antiphospholipid syndrome (APS) consist in thrombotic and obstetric events, including severe preeclampsia (PE). Because little is…
Abstract Number: 1511 • ACR Convergence 2020
Clinical Features and Select Dysregulated Immune Parameters Distinguish Blood Relatives Who Remain Clinically Stable or Progress to Incomplete Lupus or Classified SLE in the Lupus Autoimmunity in Relatives (LAUREL) Follow-up Cohort
Melissa Munroe¹, Kendra Young², Jill Norris³, Joel Guthridge⁴, Diane Kamen⁵, Timothy Niewold⁶, Gary Gilkeson⁷, Michael Weisman⁸, Mariko Ishimori⁹, Daniel Wallace¹⁰, David Karp¹¹, John Harley¹² and Judith James¹³, ¹Oklahoma Medical Research Foundation/Progentec Diagnostics, Inc., Oklahoma City, OK, ²University of Colorado Denver, Aurora, CO, ³Colorado School of Public Health, Aurora, CO, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Medical University of South Carolina, Charleston, SC, ⁶NYU School of Medicine, New York, NY, ⁷Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁸Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, LOS ANGELES, CA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Cedars-Sinai Medical Center/UCLA, Los Angeles, CA, ¹¹UT Southwestern Medical Center, Dallas, TX, ¹²Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati, OH, ¹³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation;Department of Pathology, University of Oklahoma Health Sciences Center;Department of Medicine, University of Oklahoma Health Sciences Center, Edmond, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Unaffected blood relatives (BRs) of lupus…
Abstract Number: 1609 • ACR Convergence 2020
The Accuracy of Administrative Health Data for Identifying Patients with Rheumatoid Arthritis: A Validation Study Using Medical Records in Western Australia
Khalid Almutairi¹, Johannes Nossent¹, David Preen¹, Helen Keen¹, Katrina Rogers² and Charles Inderjeeth¹, ¹The University of Western Australia, Perth, Western Australia, Australia, ²Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
Background/Purpose: The use of large administrative health datasets is increasingly important in Rheumatology for disease trends and outcome research. We established the West Australian Rheumatic…
Abstract Number: 1863 • ACR Convergence 2020
Clinical History as Tool for Diagnosis and Classification of Patients with Ankylosing Spondylitis (Axial Spondyloarthritis): Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort
Sjef van der Linden¹, Zhixiu Li², Matthew Brown³, Peter Villiger⁴, Heinz Baumberger⁵, Hermine Zandwijk⁶ and Muhammad Khan⁷, ¹Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Bern, Switzerland, Mortroux, Belgium, ²Queensland University of Technology (QUT), Translational Genomics Group, School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Translational Research Institute, Princess Alexandra Hospital, Brisbane, Qld, Australia, Brisbane, Queensland, Australia, ³Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁴Department of Rheumatology, Immunology and Allergology, University of Bern, Inselspital, Switzerland, Bern, Switzerland, ⁵Retired, Flims, Tajikistan, ⁶Retired, Mortroux, Belgium, ⁷Case Western Reserve University, Cleveland OH, Westlake, OH
Background/Purpose: Lack of sensitivity or specificity of symptoms may induce uncertainty in diagnosis and classification of AS/axSpA. We investigated if balanced sensitivity and specificity of…
Abstract Number: 0092 • ACR Convergence 2020
Diagnosis of Behçet’s Disease: Comparison of Two Sets of Classification Criteria. Application in 111 Patients of a Well-defined Population
David Martinez-Lopez¹, Alba Herrero Morant², Carmen Alvarez-Reguera², Lara Sanchez-Bilbao², Inigo Gonzalez-Mazon³, José Luis Martín-Varillas⁴, Guillermo Suarez-Amorin², Patricia Setien-Preciados², Cristina Mata-Arnaiz⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Sierrallana, Torrelavega, Spain, ⁵Hospital de Laredo, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Behçet’s disease (BD) is a systemic, chronic, relapsing vasculitis with no pathognomonic diagnostic test. The most widely used classification criteria are those of the…
Abstract Number: 1870 • ACR Convergence 2020
Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
Pamela F. Weiss¹, Timothy G. Brandon², Amita Aggarwal³, Ruben Burgos-Vargas⁴, Robert Colbert⁵, Gerd Horneff⁶, Rik Joos⁷, Ronald Laxer⁸, Kirsten Minden⁹, Angelo Ravelli¹⁰, Nicolino Ruperto¹¹, Judith Smith¹², Matthew Stoll¹³, Shirley Tse¹⁴, Filip Van den Bosch¹⁵ and Raymond Naden¹⁶, ¹Children's Hospital of Philadelphia, Philadelphia, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ⁴Department of Rheumatology, General Hospital of Mexico, Ciudad de Mexico, Mexico, ⁵Pediatric Clinical Trials Unit and Office of Clinical Director, NIAMS, NIH, Bethesda, MD, ⁶Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ⁷Ziekenhuis Netwerk Antwerpen, Basel, Switzerland, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, ¹⁰Università degli Studi di Genova, Genoa, Italy, ¹¹PRINTO, Istituto Giannina Gaslini, Genova, Italy, ¹²University of Wisconsin, Madison, WI, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴SickKids, Toronto, ON, Canada, ¹⁵Ghent University Hospital, Ghent, Belgium, ¹⁶Department of Medicine, Middlemore Hospital, Auckland, Auckland, New Zealand
Background/Purpose: The lack of pediatric classification criteria for axial disease is a major impediment to the conduct of clinical trials for juvenile spondyloarthritis (SpA). Classification…

« Previous Page
1
…
4
5
6
7
8
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.